GlycoMar's strategy is to combine the development of a portfolio of new drug candidates with complementary products and services which provide early stage income. This approach will reduce the Company's dependence on investment and increase its valuation when seeking investment.
At the heart of GlycoMar's business strategy lies the long-term development of new anti-inflammatory drug candidates. These candidates will be progressed through early stage functional screening and chemical characterisation, through to proof of concept clinical trials. The company will then secure income from licensing fees, milestone payments and subsequent royalty payments
The Company's core business is the discovery of new compounds from marine organisms, with a specific focus on glycobiology. The company combines the capabilities for isolation and early characterisation of new compounds with primary cell based screening for identifying lead compounds.
GlycoMar is generating early income through the production of specialist marine natural products for the biopharmaceutical and research market, and through the provision of screening and consultancy services.
